Beth Hecht Sells 16,666 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $8.01, for a total transaction of $133,494.66. Following the completion of the sale, the insider owned 1,144,462 shares of the company’s stock, valued at approximately $9,167,140.62. The trade was a 1.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Wednesday, July 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.03, for a total transaction of $133,827.98.
• On Monday, June 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $6.06, for a total transaction of $101,002.02.

Xeris Biopharma Price Performance

Shares of XERS opened at $8.11 on Thursday. Xeris Biopharma Holdings, Inc. has a 1-year low of $5.25 and a 1-year high of $10.08. The stock has a market cap of $1.40 billion, a PE ratio of 135.17 and a beta of 0.66. The firm has a 50-day simple moving average of $7.62 and a two-hundred day simple moving average of $6.79. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The firm had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. As a group, analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.80.

Institutional Investors Weigh In On Xeris Biopharma

Several large investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC acquired a new position in Xeris Biopharma during the 4th quarter worth approximately $25,000. KBC Group NV acquired a new stake in shares of Xeris Biopharma in the 1st quarter valued at $27,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Xeris Biopharma by 9,276.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after purchasing an additional 7,421 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Xeris Biopharma by 29.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after purchasing an additional 1,820 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its stake in shares of Xeris Biopharma by 179.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after purchasing an additional 5,000 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.